About 4th Annual Pharma Market Access and Pricing Asia

2019 Key Discussions

  • Adapting to the changing requirements of market access
  • Regional regulatory trends for impacting market penetration
  • Digital disruption and impact on RWE, HEOR and market access
  • Pricing and Access strategies for branded generics
  • Capturing the growth in Asia’s Oncology marketthrough effective pricing and market access approaches
  • Challenges and opportunities for key segments e.g. biosimilars, vaccines, anti-infectives
  • Value Based Contracting and Risk Share Agreements, and effectiveness of value-based pricing models
  • Evaluating out of the box approaches by pharma to fund access to its own medicines
  • The use of RWE in drug development and regulatory decision making vs. the use for drug pricing and reimbursement
  • Early access environment and early access data
  • Pricing and reimbursement models in ASEAN
  • Pharma – Insurance partnerships and developments in co pay / co insurance
  • Regional regulatory roadmap on reimbursement
  • Comparison of RWE across regulatory bodies

 “Excellent event! Looking at multiple perspective from patients, policy maker, prescriber, provider, and payers. Well done to the producer and organizing team!”

Sebastien Boisseau, Market Access Director, Mundipharma